Clinical trials: Interventions
Respiratory Infections in Children
Infant Formula and Toddler Drink Feeding Intervention
The purpose of this randomized, multi-center, controlled, double-blind, parallel study is to evaluate the health and developmental outcomes of children fed a new infant formula and toddler drink through 24 months of age.
- Trial name
- NCT04495738
- Testing
- Control Infant Formula, Control Toddler Drink, Experimental Infant Formula
- Where
- 27 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Coronary Artery Disease
DESyne X2 Post Market Follow-up Study
A single-arm post-market clinical follow-up study to confirm that the DESyne X2 delivery system performs similarly to the DESyne delivery system.
- Trial name
- NCT04375085
- Testing
- Percutaneous Coronary Intervention
- Where
- 3 sites in China
- Volunteers
- 49 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
Phitys I™ Percutaneous Left Ventricular Assist System Study
The primary purpose of this clinical trial is to evaluate the safety and efficacy of the percutaneous left ventricular assist system versus intra-aortic balloon pump (IABP) for Circulatory Support during High-risk PCI.
- Trial name
- NCT06357026
- Testing
- Percutaneous Ventricular Assist System（Phigine Medical）, intra-aortic balloon pump (IABP)
- Where
- 8 sites in China
- Volunteers
- 344 people
- Sponsor
- Shanghai NewMed Medical Co., Ltd.
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Overweight/Obesity
A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study. All trial participants are required to use TQF3250 capsules or placebo.
- Trial name
- NCT07798284
- Testing
- TQF3250 capsules
- Where
- 10 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cardiovascular Disease.
Access Safety and Efficacy Post Endovascular Intervention
The goal of this study is to assess the safety and effectiveness of the AXERA Access System in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary Intervention (PCI) and/or Peripheral Vascular…
- Trial name
- ASPEN (NCT01773148)
- Testing
- Arstasis Access System (AXERA)
- Where
- 17 sites in United States
- Volunteers
- 240 people
- Sponsor
- Arstasis, Inc.
Hepatitis C, Chronic
A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
In this randomized, cross-over, open label study the correlation of Pegasys (peginterferon alfa-2a) pharmacokinetics after intravenous (iv) and subcutaneous (sc) administration with viral load and viral kinetics will be…
- Trial name
- NCT01337375
- Testing
- peginterferon alfa 2a [Pegasys], peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Percutaneous Coronary Intervention
GRX With ReMOTE: First in Human in India
To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during…
- Trial name
- NCT03705481
- Testing
- Remote treatment of PCI.
- Where
- India
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Mental Health Wellness 1, Preterm Birth
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth.
- Trial name
- MLI (NCT05012072)
- Testing
- The Mastery Lifestyle Intervention
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Microgen LLC
Migraine Disorders, Migraine
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of…
- Trial name
- NCT00240630
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 50 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Hypertension
Precision Nudging for Hypertension Management: Observational Study
The purpose of the proposed observational study is to explore the relations between data-driven personalization and equitable health outcomes in a digital health intervention (DHI) for hypertension management.
- Trial name
- NCT06354192
- Testing
- Precision Nudging for Hypertension Management
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- Lirio
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Occlusion, Acute Coronary Syndrome
Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization
The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier, HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for surgical patients, has the ability to…
- Trial name
- NCT00479895
- Testing
- Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Biopure Corporation
Coronary Artery Disease, Drug-eluting Stent
Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention
Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent.
- Trial name
- NCT03049657
- Testing
- Angiolite, Xience
- Where
- 11 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Cardiva2 S.L.
To Understand the Characteristics of Digital Mental Health Intervention Users as They Relate to Mental Health Outcomes
How Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes
The goal of this observational study is to understand the characteristics of Woebot users as they relate to clinical outcomes. The objectives it aims to address are: 1.
- Trial name
- NCT05672745
- Testing
- WB-LIFE
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Woebot Health
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab…
- Trial name
- SAkuraBonsai (NCT05269667)
- Testing
- Satralizumab 120 mg
- Where
- 3 sites in United States, South Korea and 1 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Myocardial Infarction
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood…
- Trial name
- NCT00046228
- Where
- 227 sites in United States, Argentina and 17 more
- Volunteers
- 2,461 people
- Sponsor
- Centocor, Inc.
Acute Myocardial Infarction
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
- Trial name
- NCT00271765
- Testing
- INO-1001
- Where
- 16 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Diabetes
Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients
The purpose of the study is to determine the safety, acceptability and the efficacy of a 12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic control in type 2 diabetic patients with or at risk…
- Trial name
- NCT01241695
- Testing
- Oral nutritional supplement, food for special medical purposes
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Fresenius Kabi
Pancreatic Cancer
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy.
- Trial name
- NCT00121745
- Testing
- Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Epeius Biotechnologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.